Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Publication

Advanced patient-derived lung tumoroids to identify limiting factors for oncolytic virotherapy

H. Le et al.AACR 2023Download the poster herePoster Presentation

Published 19 April 2023
Categorized as -others, 2023, Invir.IO, Publication

PoxSTG, a novel chimeric poxvirus with improved oncolytic potency

P Erbs et al.AACR 2023Download the poster herePoster Presentation

Published 19 April 2023
Categorized as -others, 2023, Invir.IO, Publication

Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer

A. Lalane et al.AACR 2023Download the poster herePoster Presentation

Published 18 April 2023
Categorized as 2023, Myvac, Publication, TG4050

A randomized phase II trial of TG4001 plus avelumab versus avelumab alone in recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16 positive anogenital cancers

C. Le Tourneau, et al. AACR 2023 – Download the Poster

Published 17 April 2023
Categorized as -others, 2023, Publication, TG4001, TG4001

Oncolytic virus TG6002 safety and activity after intrahepatic artery administration in patients with liver-dominant metastatic colorectal cancer

A. Samson, et al. AACR 2023 – Download the Poster

Published 17 April 2023
Categorized as -others, 2023, 2025, Publication

Selection of an optimal anti-PD-L1 single domain antibody format for the vectorization into oncolytic vaccinia virus and the generation of bispecific immunomodulators

JB. Marchand et al.AACR 2023Download the poster herePoster Presentation

Published 17 April 2023
Categorized as -others, 2023, Invir.IO, Publication

TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses

JB. Marchand et al.AACR 2023Download the poster herePoster Presentation

Published 16 April 2023
Categorized as 2023, Invir.IO, Publication, TG6050-en

Extracellular vesicles (EV): mediators of therapeutic vaccination? In vivo and in vitro characterization of EVs generated after infection of human and murine cells with therapeutic poxviruses

L. Walther et al.AACR 2023Download the poster herePoster Presentation

Published 16 April 2023
Categorized as -others, 2023, Publication

Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and heck carcinoma (HNSCC)

JP Delord, et al. ASCO 2022 Abstract available on the ASCO website – Download the poster here Poster Presentation

Published 6 June 2022
Categorized as 2022, Myvac, Publication, TG4050

Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination

Rodrigo Nalio Ramos, et al. Clinical and Translational Immunology, May 8 2022 – Read the article Publication

Published 8 May 2022
Categorized as -others, 2022, Publication

Posts pagination

Newer posts Page 1 … Page 4 … Page 13 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu